secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-02-05T23:59:59+00:00
Accession:  0001193125-26-039425
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

LXEO Head of Research Dr. Adler departs; transition agreement through July 31, 2026
--------------------------------------------------------------------------------

- Dr. Adler stepped down as Head of Research effective February 1, 2026; will provide advisory services through July 31, 2026 or earlier termination.
- Under transition agreement, Dr. Adler will receive up to $62,500 in monthly installments; service-vesting equity continues to vest during transition period.
- Option exercise period extended to six months after transition end; additional $1,000 lump sum possible upon execution of supplemental release.
- Transition agreement includes customary release of claims, non-disparagement, and cooperation provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526039425/0001193125-26-039425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526039425/lxeo-20260130.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-039425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer